These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28674184)

  • 1. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
    Wu PK; Hong SK; Park JI
    Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase.
    Wu PK; Hong SK; Veeranki S; Karkhanis M; Starenki D; Plaza JA; Park JI
    Mol Cell Biol; 2013 Oct; 33(20):4051-67. PubMed ID: 23959801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sp1 regulates Raf/MEK/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells.
    Karkhanis M; Park JI
    Cell Signal; 2015 Mar; 27(3):479-86. PubMed ID: 25595558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortalin (HSPA9) facilitates
    Wu PK; Hong SK; Chen W; Becker AE; Gundry RL; Lin CW; Shao H; Gestwicki JE; Park JI
    Sci Signal; 2020 Mar; 13(622):. PubMed ID: 32156782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf
    Wu PK; Hong SK; Park JI
    Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability.
    Wu PK; Hong SK; Starenki D; Oshima K; Shao H; Gestwicki JE; Tsai S; Park JI
    Oncogene; 2020 May; 39(21):4257-4270. PubMed ID: 32291414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Lloyd RV; Park JI
    Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
    Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
    Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
    Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.
    Falck Miniotis M; Arunan V; Eykyn TR; Marais R; Workman P; Leach MO; Beloueche-Babari M
    Cancer Res; 2013 Jul; 73(13):4039-49. PubMed ID: 23639941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.
    Brennan DF; Dar AC; Hertz NT; Chao WC; Burlingame AL; Shokat KM; Barford D
    Nature; 2011 Apr; 472(7343):366-9. PubMed ID: 21441910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
    Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
    Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.